SEMA3B improves the survival of patients with esophageal squamous cell carcinoma by upregulating p53 and p21
Hong Tang(First Affiliated Hospital of Jiangxi Medical College), Yufeng Wu(Peking University), Hongyan Wang(Qingdao National Laboratory for Marine Science and Technology), Yanru Qin(First Affiliated Hospital of Zhengzhou University), Lili Wang(Zhengzhou University), Ming Liu(Sun Yat-sen University), Haiying Wang(Southern Medical University), Qiming Wang(Hunan Cancer Hospital), Hui Zhu(Sun Yat-sen University), Junpeng Luo(Henan University Huaihe Hospital and Huaihe Clinical Institute), Zheng He(Zhengzhou University), Shaomei Li(Huazhong Agricultural University)
Cited by 22
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
Association analyses identify six new psoriasis susceptibility loci in the Chinese population
|Nature Genetics|2010|317
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311